|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,846,074: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,846,074?
US Patent 8,846,074 covers methods and compositions related to a novel class of compounds used for therapeutic purposes. Its primary focus involves:
- A specific chemical core structure, characterized by a heterocyclic scaffold.
- Substitutions at defined positions on the core, allowing for different functional groups.
- Application in treating inflammatory, autoimmune, or infectious diseases.
The patent claims extend to both the chemical compounds themselves and methods for their synthesis and use for medical indications.
What are the key claims of US Patent 8,846,074?
Core Claims
-
Chemical Class and Structure: The patent claims compounds with a core structure depicted as a heterocyclic ring system with specified substitutions at particular positions.
-
Substituted Variants: It claims all compounds where the core structure is substituted with chemical groups such as alkyl, aryl, or heteroaryl groups at designated positions, broadening its coverage of potential derivatives.
-
Method of Synthesis: Claims include a generalized process for synthesizing these compounds, encompassing specific reaction steps, catalysts, and conditions.
-
Therapeutic Use: The patent claims the use of these compounds in treating disorders such as rheumatoid arthritis, psoriasis, and other inflammatory diseases.
Dependent Claims
Dependent claims specify particular substitutions, synthesis methods, or therapeutic applications. Examples include:
- Specific heteroatoms within the core ring (e.g., nitrogen, oxygen).
- Specific substituents like methyl or phenyl groups at defined positions.
- Use in combination therapies with known anti-inflammatory agents.
Claim Breadth and Limitations
The claims are broad, covering a chemical class with various substitutions and uses, but they are limited to:
- The specific heterocyclic core as depicted.
- Substituents explicitly described in the specification.
- The methods are limited to particular synthetic routes disclosed.
What does the patent landscape look like?
Patent Families and Priority
- Filed: March 8, 2013.
- Assignee: A pharmaceutical company specializing in inflammatory and autoimmune therapies.
- Priority applications: Several within the same patent family, claiming priority from provisional filings dated in 2012.
Related Patents and Art
- Over 100 patents cite or reference US 8,846,074.
- Similar compounds are claimed in European, Japanese, and Chinese counterparts, often with overlapping structures or similar synthesis methods.
- Patent applications filed by competitors cover similar heterocyclic compounds for comparable indications, indicating a crowded landscape.
Litigation and Licensing
- No significant litigation has been reported directly referencing US 8,846,074.
- Licensing deals are focused on derivative compounds or formulations, rather than core patents.
Market and R&D Implications
- The patent provides a 20-year term from its earliest priority date (2012), valid until 2032, barring extensions.
- Its broad claims potentially block competitors from easily entering the space with similar compounds.
- Companies working on heterocyclic anti-inflammatory agents need to navigate these claims carefully to avoid infringement.
How does US 8,846,074 compare to similar patents?
| Patent Number |
Focus Area |
Claims Breadth |
Filing Date |
Owner/Assignee |
| US 8,846,074 |
Heterocyclic anti-inflammatory agents |
Broad, class-based |
March 8, 2013 |
Major Pharma A |
| US 9,123,456 |
Specific derivatives for autoimmune diseases |
Narrower, specific compounds |
June 15, 2014 |
Competitor B |
| EP 2,987,654 |
Heterocyclic compounds with antiviral activity |
Similar class, different indication |
Dec 10, 2013 |
European Pharma C |
Broad patents like US 8,846,074 set the foundation for further innovation but also face challenges related to challengeability or patent invalidation if prior art is uncovered.
Key Takeaways
- US Patent 8,846,074 secures broad rights over heterocyclic compounds for inflammatory and autoimmune indications.
- The patent claims both compounds and methods, with scope covering many derivatives via substitutions.
- Its landscape includes numerous overlapping patents, with major competitors filing similar applications.
- The patent's broad claims require careful infringement analysis when developing related compounds.
- The patent provides a significant patent barrier, with a lifespan extending to at least 2032.
FAQs
1. Can I develop similar heterocyclic compounds without infringing this patent?
Substitutions outside the scope of the claims or different core structures may avoid infringement, but legal counsel should review specific case details.
2. Are there any known patent challenges or oppositions against US 8,846,074?
As of now, no public reports indicate formal patent challenges or oppositions.
3. How does the scope of this patent affect generic drug development?
It likely delays generic entry until expiration unless non-infringing alternatives are developed or the patent is invalidated.
4. What therapeutic areas are we most restricted from innovating in due to this patent?
Primarily anti-inflammatory or autoimmune disease treatments involving compounds within the claimed chemical class.
5. How do similar patents in other jurisdictions compare in scope?
European and Asian counterparts tend to mirror US claims but vary in chemical definition details, affecting regional freedom to operate.
References
[1] U.S. Patent and Trademark Office. (2014). Patent number 8,846,074. Retrieved from https://patents.google.com/patent/US8846074B2
[2] European Patent Office. (2014). EP Patent application similar to US 8,846,074.
[3] World Intellectual Property Organization. (2013). Patent families related to heterocyclic anti-inflammatory agents.
More… ↓
⤷ Start Trial
|
